Bio Green Med Solution, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. The company provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
最新の財務諸表(Form-10K)によると、Bio Green Med Solution Incの総資産は$0で、純損失は$0です。
BGMSの主要な財務比率は何ですか?
Bio Green Med Solution Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Bio Green Med Solution Incの収益はセグメントまたは地域別にどのように分けられていますか?
Bio Green Med Solution Inc の最大収益セグメントは Fire Safety Equipment で、最新の利益発表における収益は 603,000 です。地域別に見ると、Malaysia が Bio Green Med Solution Inc の主要市場であり、収益は 747,000 です。
Bio Green Med Solution Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Bio Green Med Solution Incの純損失は$0です。